Article thumbnail

Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease

By Patrick M. Flood, Li Qian, Lynda J. Peterson, Feng Zhang, Jing-Shan Shi, Hui-Ming Gao and Jau-Shyong Hong


Parkinson's disease (PD) is a neurodegenerative condition characterized by chronic inflammation. Nuclear factor κB (NF-κB) is a family of inducible transcription factors that are expressed in a wide variety of cells and tissues, including microglia, astrocytes, and neurons, and the classical NF-κB pathway plays a key role in the activation and regulation of inflammatory mediator production during inflammation. Activation of the classical NF-κB pathway is mediated through the activity of the IKK kinase complex, which consists of a heterotrimer of IKKα, IKKβ, and IKKγ subunits. Targeting NF-κB has been proposed as an approach to the treatment of acute and chronic inflammatory conditions, and the use of inhibitors specific for either IKKβ or IKKγ has now been found to inhibit neurodegeneration of TH+ DA-producing neurons in murine and primate models of Parkinson's disease. These studies suggest that targeting the classical pathway of NF-κB through the inhibition of the IKK complex can serve as a useful therapeutic approach to the treatment of PD

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A .D .R e y n o l d s ,J .G .G l a n z e r ,I .K a d i ue ta l . ,“ N i t r a t e da l p h a -synuclein-activated microglial profiling for Parkinson’s disease,”
  2. (2007). A .L .B a r t e l sa n dK .L .L e e n d e r s ,“ N e u r o i n fl a m m a t i o ni n the pathophysiology of Parkinson’s disease: evidence from animal models to human in vivo studies with [C]-PK11195
  3. (2008). a k k a r ,J .W a n g ,K .J .L a d n e re ta l .
  4. (2003). a m a m o t o ,U .N .V e r m a ,S .P r a j a p a t i ,K .Y o u n - T a e ,a n dR
  5. (2005). A selective novel low-molecular-weight inhibitor of IκBk i n a s e - β (IKKβ) prevents pulmonary inflammation and shows broad antiinflammatory activity,”
  6. (2009). A structural guide to proteins of the NF-kappaB signaling module,”
  7. (2000). a y ,F .D ’ A c q u ist o ,L.A .M ad g e ,J .G loc kne r ,J .S.P ob e r
  8. (2000). ag at su ,M.M ogi,H .I c hinose ,andA .T og ari,“ C hang e sin cytokines and neurotrophins in Parkinson’s disease,”
  9. (2005). Amelioration of acute inflammation by systemic administration of a cellpermeable peptide inhibitor of NF-κBa c t i v a t i o n ,
  10. Amelioration of chronic murine colitis by peptide-mediated transduction of the IκB kinase inhibitor NEMO binding domain peptide,”
  11. (2008). andM.F.Neurath, “NF-κB ininflammatory bowel disease,”
  12. (2005). B l o c ka n dJ .S .H o n g ,“ M i c r o g l i aa n di n fl a m m a t i o n -mediated neurodegeneration: multiple triggers with a commonmechanism,”Progress in Neurobiology,v ol.76,no .2,p p .
  13. (2005). Bautista-Hern´ andez et al., “Increased plasmalevelsofTNF-α butnotofIL1-β inMPTPtreated monkeys one year after the MPTP administration,” Parkinsonism and Related Disorders,
  14. (2007). Beyond IκBs: alternative regulation of NF-κBa c t i v i t y ,
  15. (2003). Biologic sequelae of c-Jun NH-terminal kinase (JNK) activation in multiple myeloma cell lines,”
  16. (1988). cGeer ,S.I tagaki,B.E.Boy es,andE.G.M cGeer ,“R eactivemicrogliaarepositiveforHLA-DRinthesubstantianigra of Parkinson’s and Alzheimer’s disease brains,”
  17. (2011). Chen et al.,“β2-adrenergic receptoractivationpreventsrodentdopaminergicneurotoxicityby inhibitingmicrogliavia anovel signalingpathway,”Journal of Immunology,
  18. (2010). Conditional ablation of Ikkb inhibits melanoma tumor development in mice,”
  19. (2008). Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture,”
  20. (2010). Curcumin reduces α-synuclein induced cytotoxicity
  21. (2003). D .Strahl,andA.S.Bald win,“ AnucleosomalfunctionforIκB kinase-α in NF-κB-dependent gene expression,” Nature,v o l .
  22. (2010). D a h l m a n ,N .B a k k a r ,W .H e ,a n dD .C .G u t t r i d g e ,“ N F -κB functions in stromalfibroblaststo regulate early postnatal muscle development,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .
  23. (2002). Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B)from IkappaB and in phosphorylatingthe p65 subunit of NF-kappa
  24. (2003). Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains,”
  25. (2005). Do pathogen exposure and innate immunity cause brain diseases?”
  26. (2003). e i s s n e r ,C .P r u n i e r ,D .G u i l l o t e a u ,S .C h a l o n
  27. (2004). E.Jimi,K.Aoki,H.Saitoet al.,“Selective inhibitionofNF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo,”
  28. (2006). Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells,”
  29. Epicutaneously induced TGF-β-dependent tolerance inhibits experimental autoimmune encephalomyelitis,”
  30. (2009). Ex vivo inhibition of NF-κB signaling in alloreactive T-cells prevents graft-versus-host disease,”
  31. (2010). Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis,”ImmunologicalReviews,vol.233,no.1,pp.55– 61,
  32. (1988). Glutamate neurotoxicity and diseases of the nervous system,”
  33. (2009). Glutamate, excitotoxicity, and programmed cell death in parkinson disease,”
  34. (2005). H i r s c h ,S .H u n o t ,a n dA .H a r t m a n n ,“ N e u r o i n fl a m -matory processes
  35. (2007). h i r u m a n g a l a k u d i ,L .Y i n ,H .V .R a o ,a n dP .G r a m m a s , “IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons,”
  36. (2007). IKKβ inhibition attenuates myocardial injury and dysfunction followingacute ischemia-reperfusion injury,”
  37. (1986). Inducibility of K immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism,”
  38. (2007). Inflammation in Parkinson’s diseases and other neurodegenerative diseases: cause and therapeutic implications,”Current
  39. (2010). Inflammatory neurodegeneration and mechanisms of microglial killing of neurons,”
  40. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges,”
  41. (2010). Inhibition of IκBk i n a s e - β protects dopamine neurons againstlipopolysaccharide-induced neurotoxicity,”
  42. (2004). IκBk i n a s e - α acts in the epidermis to control skeletal and craniofacial morphogenesis,”
  43. Kneitz et al., “KINK-1, a novel small-molecule inhibitor of IKKβ, and the susceptibility of melanoma cells to antitumoral treatment,”
  44. (2009). L a t a n i c ha n dL .H .T o l e d o - P e r e y r a ,“ S e a r c h i n gf o rN F -κB-based treatments of ischemia reperfusion injury,”
  45. (1994). Loeffle r ,A .J .D e M a g g i o ,P .L .J u n e a u ,M .K .H a v a i c h
  46. (2001). Mesodermal patterning defect
  47. (2008). Microglial cells and Parkinson’s disease,”
  48. (2001). Microglial chemotaxis, activation, and phagocytosis ofamyloid β-peptide as linked phenomena inAlzheimer’sdisease,”Neurochemistry
  49. (1996). Molecular mechanisms of microglial activation,”
  50. (1986). Multiple nuclear factors interact with the immunoglobulin enhancer sequences,”
  51. (2004). N.Sizemor e,A.A garwal,K.Dasetal.,“I nhibit orofκBki n ase is required to activate a subset of interferon γ-stimulated genes,”
  52. NADPH oxidase inhibitor DPI is neuroprotective at femtomolar concentrations through inhibition of microglia over-activation,”
  53. (2009). Neuroinflammation in the living brain of Parkinson’s disease,”
  54. (2010). Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy,” J o u r n a lo fN e u r a lT r a n s m i s s i o n ,
  55. (2002). Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and
  56. (2010). Neuroprotective potential of the NF-[kappa]B inhibitor peptide IKK-NBD in cerebral ischemia-reperfusion injury,”
  57. (2001). NF-κB in transplantation: friend or foe?” Transplant Infectious Disease,v o l .3 ,n o .4 ,p p .
  58. (2010). NF-κB signaling: a tale of two pathways in skeletal myogenesis,”
  59. (2001). NF-κB: a key role in inflammatory diseases,”
  60. (2002). NF-κBa sa therapeutic target in multiple
  61. (1996). Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease,”
  62. (2007). Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation,”
  63. (2008). Nuclear factor-κB1: regulation and function,”
  64. (1997). Nuclear translocation of NF-κb is increased in dopaminergic neurons of patients with Parkinson disease,”
  65. (1994). o g i ,M .H a r a d a ,T .K o n d o be ta l . ,“ I n t e r l e u k i n - 1 β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients,”
  66. (2007). o g i ,T .K o n d o ,Y .M i z u n o ,a n dT .N a g a t s u
  67. (1998). Oxidative mechanisms in nigral cell death
  68. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration,”
  69. Parkinson’s disease:
  70. (2003). Presence of reactive microglia in monkey Substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration,”
  71. (2008). Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson’s disease does not involve activation of caspase-9
  72. (1995). Q u r e s h i ,S .B a i g ,I .B e d n a r ,P .S o d e r s t e
  73. (2004). r a i ,T .F u r u y a ,T .Y a s u d a ,M .M i u r a ,Y .M i z u n o ,a n d H. Mochizuki, “Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice,”
  74. (2009). Ransohoff a n dV .H .P e r r y ,“ M i c r o g l i a lp h y s i o l o g y : unique stimuli, specialized responses,”
  75. (1999). Regulation of interleukin-8 gene expression,”
  76. (1997). RelB regulation of chemokine expression modulates local inflammation,”
  77. (2007). Role of NF-κBi n transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-α,”
  78. (2010). Role of nuclear factor kappaB in cardiovascular healthanddisease,”Clinical Science,vol.118,no.10,pp. 593– 605,
  79. (2004). S.H ong,H .C .K im,W .Zhang,andM.L.Bloc k, “Morphinan neuroprotection: new insight into the therapy of neurodegeneration,”
  80. (2010). Sch¨ o n ,N .P l e t z ,K .W a l l b r e c h t ,L .E r p e n -beck, and M. Sch¨ on, “NF-κB inhibition through proteasome inhibition or ikkβ blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways,”
  81. (2000). Severe liver degeneration and lack of NF-κBa c t i v a t i o ni nN
  82. (1999). Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP1a n dN F - κB,”
  83. (2001). t r l e ,J .H .Z h o u ,W .H .S h e ne ta l . ,“ I n t e r l e u k i n -
  84. (2010). The IkappaB kinase inhibitor nuclear factor-kappaB essential modulator-binding domain peptide for inhibition of balloon injury-induced neointimal formation,” Arteriosclerosis, Thrombosis, and Vascular Biology,v o l .
  85. (2010). The IKK complex, a central regulator of NFkappaB activation,”
  86. The IκB kinase(IKK) inhibitor,NEMO-binding domainpeptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis,” J o u r n a lo fB i o l o gi c a lC h em i s t ry ,
  87. (2009). The NF-kappaB family of transcription factors and its regulation,”
  88. (2009). The nuclear factor NF-kappaB pathway in inflammation,”
  89. (2002). The p65/RelA subunit of NF-κB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor,”
  90. (2010). The pivotal role of the alternative NF-κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis,”
  91. (2010). The resolution of inflammation: anti-inflammatory roles for NF-κB,”
  92. (2008). The roles of the classicalandalternativenuclearfactor-κBpath ways:pot ential implications for autoimmunity and rheumatoid arthritis,”
  93. (2008). TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease,”
  94. (2005). TRAF2: a double-edged sword?”
  95. (1995). Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-κB,”
  96. (2002). Transforming growthfactor-β1 increasesbad phosphorylationandprotects neurons againstdamage,”
  97. (1994). Tumor necrosis factor-α (TNF-α)i n c r e a s e s both in the brain and in the cerebrospinal fluid from parkinsonianpatients,”NeuroscienceLetters,vol.165,no.1-2,
  98. (2002). Two pathways to NF-κB,”
  99. (2008). Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression,”
  100. (2007). X.Liu et al.,“Selective inhibition ofNF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease,”